C-Path’s CURE Drug Repurposing Collaboratory Aims to Document 1,000 Cases on the CURE ID App for Long COVID Awareness Day

TUCSON, Ariz., March 15, 2024 — Critical Path Institute’s (C-Path) CURE Drug Repurposing Collaboratory (CDRC), a leading advocate for healthcare innovation, is proud to announce its active participation in Long COVID Awareness Day, which will be observed today, March 15. 

LCovid Square

Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), is a complex and debilitating condition characterized by persistent symptoms that continue for weeks or months after the acute phase of COVID-19. As part of their commitment to advancing understanding and research into long COVID, CDRC and CURE ID have set a bold goal to document 1,000 cases of long COVID on CURE ID by March 31. 

CURE ID is a joint U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) initiative that allows healthcare professionals, patients, and care partners to share and discuss using existing drugs in new ways to treat diseases with high unmet needs. By documenting cases of long COVID on CURE ID, healthcare providers, patients, and care partners can contribute valuable insights into the diverse manifestations and management of this condition, ultimately guiding future research and treatment strategies. 

“Our participation in Long Covid Awareness Day highlights our unwavering commitment to advancing healthcare innovation and improving patient outcomes,” said Claire Bassetti, Communication and Patient Engagement Manager at CDRC. “By collaborating with healthcare professionals, patients, and care partners we can leverage platforms like CURE ID, that aim to accelerate progress in understanding and addressing the challenges posed by long COVID.”  

In addition to documenting cases on CURE ID, CDRC will engage in various awareness-raising activities to educate the public about long COVID and its impact on individuals and communities. These efforts will include social media campaigns, attending long COVID webinars and collaborations with patient advocacy groups.  CDRC is also actively engaged in a randomized trial investigating repurposed treatments for Long COVID. For further details about this initiative, including study specifics, please visit the ClinicalTrials.gov site, here.  

CDRC invites healthcare professionals, researchers, patients, and individuals affected by long COVID to join its mission to document 1,000 cases on CURE ID by March 31, 2024. Together, we can make a meaningful difference in advancing research and improving the lives of those affected by long COVID. 

For more information about Long COVID Awareness Day and CDRC’s initiatives, please visit CURE-ID (ncats.io) or contact Claire Bassetti at cbassetti@c-path.org, and like and follow us on LinkedIn and X.  

About Critical Path Institute 

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.